Lipid Nanoparticles
Custom Design & CRO Service

End-to-end lipid nanoparticle formulation — from early-stage screening and payload encapsulation to scale-up GMP manufacturing.

Powered by our proprietary NanoGenerator® microfluidic platform and ionizable lipids library.

Request a Project Quote

Explore Our Service

PreciGenome offers nanoparticle formulation services for mRNA-LNP, liposome, PLGA research and development service.

Lipid nanoparticles have emerged across the pharmaceutical industry as promising vehicles to deliver a variety of therapeutics. They are a novel pharmaceutical drug delivery system and formulation. LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle. (Learn more about LNP)

Workflow

Contact & requirements

One-to-one technical support

Submit custom service form

Project start

Product delivery

Performance

Therapeutic strategy of targeting SLPI-mediated KC reprogramming to alleviate RILD.

(A) Transmission electron microscopy (TEM) image of liposomes stained with phosphotungstic acid, revealing uniform spherical morphology.

(B) Dynamic light scattering analysis showing the particle size of blank liposomes (left, 79 nm) and siSLPI-loaded liposomes (right, 78 nm).

(C) Excitation spectrum of DiD-labeled liposomes.

(D) Time-dependent intracellular uptake of liposomes by Raw264.7 cells. Nuclei were stained with Hoechst (blue), liposomes were labeled with DiD (red), and cytoplasm was stained with Calcein AM (green).

(E) In vivo fluorescence imaging showing hepatic accumulation of liposomes at 1 h post-injection.

(F) CCK-8 assay evaluating the effect of liposomes on Raw264.7 cell proliferation.

(G) H&E staining of heart, liver, spleen, lung, and kidney tissues from treated mice (n = 5), showing no histopathological abnormalities.

(H) H&E staining of liver tissues from different treatment groups (n = 5). Blue arrows: normal hepatocytes; gray arrows: shrunken hepatocytes; green arrows: intact hepatocytes; black arrows: cytoplasmic disruption and sinusoidal dilation.

(I) Immunohistochemistry analysis of hepatic IL-1β, IL-6, and TNF-α expression in RILD mice treated with siSLPI-loaded liposomes.

(J) ELISA quantification of hepatic IL-1β, IL-6, and TNF-α levels in RILD mice treated with siSLPI-liposomes.

Reference: Int. J. Mol. Sci. 2026, 27(5), 2517

LNP mouse study from paper Synthesis and Translational Assessment .jpg

In vivo translational activity in female CD-1 mice of Fluc mRNA-LNPs prepared with PreciGenome NanoGenerator.

(A) Representative bioluminescent images at 3, 6, 12, 24, 48, and 96 h postinjection.

(B) Bioluminescence intensity of treated groups during 96 h. See the Supporting Information for the quantitative analyses of each group and their average.
Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc multiple-comparison test. No statistically significant
differences were detected among 9a, 43a, and 42a.

Reference: J. Med. Chem. 2026, 69, 5, 5811–5827

Lipid Nanoparticles and Synthesis

Nanoparticle Synthesis:

NanoGenerator™ nanoparticle synthesis system employs microfluidic device for controllable and tunable nanoparticle production.